triGLP® Bioactive Peptide Complex

 

​

Executive Summary for Physician Review ​Overview

 

 

triGLP® is a proprietary, patent-protected bioactive peptide complex derived from enzymatically hydrolyzed Atlantic salmon protein. It is designed to support metabolic efficiency, fat-specific weight reduction, preservation of lean muscle mass, gut integrity, and energy metabolism, particularly in aging and metabolically stressed populations. triGLP is classified as a New Dietary Ingredient (NDI) in the United States with self-affirmed GRAS status.

 

 

 

Distinctive Characteristics

 

 

• Unique peptide fingerprint distinct from over 1,300 commercial hydrolysates

• Bioactive signaling effects beyond nutritional protein intake

• Rapid absorption and high bioavailability

• Human-grade Norwegian Atlantic salmon source

• Non-GMO, additive-free, antibiotic-free

 

 

​

Mechanism of Action (Summary)

 

 

Preclinical and mechanistic studies indicate peptide-mediated modulation of GLP-1, GIP, and GLP-2 pathways, along with gene expression changes including upregulation of HMOX-1 (antioxidant and gut protection) and FTH1 (iron metabolism), and downregulation of ALOX-12 (inflammatory signaling). These effects appear independent of caloric or macronutrient contribution.

 

 

 

Human Clinical Findings

 

 

Metabolic Health (Healthy Adults):

~7% BMI reduction and ~10% body fat reduction over 8 weeks with no loss of body water; improved fasting glucose, reduced inflammatory markers, and increased ferritin levels.

 

Overweight Subjects:

~6% BMI reduction over 6 weeks; improved insulin sensitivity, lipid markers, and reduced IL-6.

 

Energy & Vitality:

Improved subjective energy, reduced oxidative stress, increased anti-inflammatory IL-10, and improved morning energy at doses as low as 4 g/day.

 

 

 

Lean Muscle Preservation

 

 

In vitro and preclinical data demonstrate dose-dependent inhibition of myostatin and activin A, suggesting preservation of skeletal muscle mass during weight reduction. This differentiates triGLP from pharmacologic GLP-1 agonists commonly associated with lean mass loss.

 

 

 

Gut Health & Tolerability

 

 

triGLP demonstrated improved gut structural integrity and reduced inflammation in preclinical IBD models. Human data indicate rapid absorption, improved digestibility, and minimal gastrointestinal burden compared to whey protein.

 

 

 

Clinical Relevance & Conclusion

 

 

triGLP represents a mechanistically distinct bioactive peptide intervention supporting fat-specific weight loss, lean muscle preservation, improved glucose handling, reduced inflammation, and enhanced energy metabolism. Available evidence supports favorable tolerability and clinical relevance, with further large-scale trials warranted.